Trilliome

Trilliome is a Swiss biotechnology company that develops precision microbiome ingredients aimed at healthy aging. Utilizing an AI-driven discovery platform, the company identifies and validates plant-derived bioactives designed to modulate gut microbial networks. Its lead product, TRI-01, is engineered to increase gut-resident bacteria associated with anti-inflammatory and brain-protective metabolites, targeting key features of aging such as cognitive decline, mood disturbances, and systemic inflammation. Trilliome operates at the intersection of biotechnology and nutrition, focusing on scalable, science-backed solutions for the B2B functional food and supplement sectors. By upcycling plant and fruit waste into therapeutic ingredients, the company combines medical-grade microbiome science with circular sustainability practices to improve health outcomes and longevity. Their approach is validated through human-relevant ex-vivo data and ongoing clinical development, aiming to restore the gut-brain-immune axis. The company has received significant recognition, including awards from EIT Food, Probiota, and the Aging Research and Drug Discovery conference, highlighting its innovative position in the longevity space.